- Home
- CYRX vs DBVT Comparison
CYRX vs DBVT Comparison
Compare CYRX & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYRX
- DBVT
- Stock Information
- Founded
- CYRX 1999
- DBVT 2002
- Country
- CYRX United States
- DBVT France
- Employees
- CYRX N/A
- DBVT N/A
- Industry
- CYRX Biotechnology: Pharmaceutical Preparations
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CYRX Health Care
- DBVT Health Care
- Exchange
- CYRX Nasdaq
- DBVT Nasdaq
- Market Cap
- CYRX 277.5M
- DBVT 239.9M
- IPO Year
- CYRX N/A
- DBVT N/A
- Fundamental
- Price
- CYRX $5.40
- DBVT $7.74
- Analyst Decision
- CYRX Strong Buy
- DBVT Buy
- Analyst Count
- CYRX 8
- DBVT 4
- Target Price
- CYRX $10.75
- DBVT $14.81
- AVG Volume (30 Days)
- CYRX 457.1K
- DBVT 98.4K
- Earning Date
- CYRX 05-07-2025
- DBVT 07-29-2025
- Dividend Yield
- CYRX N/A
- DBVT N/A
- EPS Growth
- CYRX N/A
- DBVT N/A
- EPS
- CYRX N/A
- DBVT N/A
- Revenue
- CYRX $232,134,000.00
- DBVT $3,497,000.00
- Revenue This Year
- CYRX N/A
- DBVT $1,700.53
- Revenue Next Year
- CYRX $9.41
- DBVT $535.67
- P/E Ratio
- CYRX N/A
- DBVT N/A
- Revenue Growth
- CYRX 11.75
- DBVT N/A
- 52 Week Low
- CYRX $4.58
- DBVT $2.21
- 52 Week High
- CYRX $11.64
- DBVT $12.78
- Technical
- Relative Strength Index (RSI)
- CYRX 37.87
- DBVT 38.67
- Support Level
- CYRX $5.91
- DBVT $8.33
- Resistance Level
- CYRX $6.16
- DBVT $9.92
- Average True Range (ATR)
- CYRX 0.41
- DBVT 0.89
- MACD
- CYRX -0.12
- DBVT -0.36
- Stochastic Oscillator
- CYRX 0.50
- DBVT 0.59
About CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.